Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIANT: Relacorilant + Nab-Paclitaxel in mPDAC
NCT04329949Phase 3Terminated
- Sponsor
- Corcept Therapeutics
- Start
- Jun 2020
- Primary completion
- Aug 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of relacorilant in pancreatic ductal adenocarcinoma (PDAC), sponsored by Corcept Therapeutics. Started Jun 2020; status: terminated.
02
Drugs
relacorilant
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04329949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04329949.